Clinical Trials
10 trialsNCT04514484 2026-05-28
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT05092373 2026-01-14
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT03170960 2025-08-17
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Exelixis
Phase 1 Active not recruiting
NCT01441947 2025-05-25
Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer
Massachusetts General Hospital
Phase 2 Completed
NCT00940225 2024-04-25
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
Exelixis
Phase 2 Completed
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT02071862 2022-07-20
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Calithera Biosciences, Inc
Phase 1 Completed
NCT03316586 2021-12-28
A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02260531 2021-05-20
Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01738438 2016-12-06
Cabozantinib for Metastatic Triple Negative BrCa
Dana-Farber Cancer Institute
Phase 2 Completed